Talk:Indacaterol/glycopyrronium bromide

Proposed changes
Hello, I am a Sunovion employee and would like to help update this Wikipedia entry. There are updates that are needed that I would like to work with you on to ensure it’s updated according to Wikipedia guidelines. I look forward to working with you.

Please add ‘In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugdeliverybusiness.com/sunovion-novartis-ink-licensing-deal-inhaled-copd-drugs/

Also, add ‘In 2017, the FDA approved Lonhala Magnair, a new drug product, to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://www.drugs.com/history/lonhala-magnair.html

Thanks for your help Ed at Sunovion (talk) 18:30, 13 December 2019 (UTC)

Reply 13-DEC-2019
Regards, Spintendo  20:25, 13 December 2019 (UTC)
 * 1) ✅ The claim regarding the commercial rights was added to the article.
 * 2) ❌ The claim regarding Lonhala Magnair was not added to the article.

Proposed changes
Hello, I am a Sunovion employee and would like to help update this Wikipedia page with this edit.

Add ‘In 2017, the FDA approved Lonhala Magnair (glycopyrrolate) Inhalation Solution for the treatment of COPD to be marketed by Sunovion Pharmaceuticals.’

The source for this edit is https://journals.sagepub.com/doi/full/10.1177/1060028018798753

Thanks for your help Ed at Sunovion (talk) 20:59, 13 December 2019 (UTC)

Reply 13-DEC-2019
Regards, Spintendo  22:10, 13 December 2019 (UTC)
 * This proposal was previously declined. The article does not exist for the promotion of new products.